High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells

Vaccine

Volumn 32, Issue 24, 2014, Pages 2770-2781

  Genzel, Yvonne ^a   Vogel, Thomas ^a,b   Buck, Johannes ^a,b   Behrendt, Ilona ^a   Ramirez, Daniel Vazquez ^a   Schiedner, Gudrun ^c   Jordan, Ingo ^d   Reichl, Udo ^a,e  

^a MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^b ESSLINGEN UNIVERSITY OF APPLIED SCIENCES   (Germany)

^c CEVEC Pharmaceuticals GmbH   (Germany)

^d PROBIOGEN AG   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Batch versus perfusion culture; Cell density effect; Cell specific virus yield; Influenza; Membrane cut off; Suspension cells

Indexed keywords

INFLUENZA VACCINE; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; BACTERIUM CULTURE; BIOREACTOR; CELL DENSITY; CELL GROWTH; CELL LINE; CELL MEMBRANE; CULTURE MEDIUM; HUMAN; HUMAN CELL; INFLUENZA VIRUS A; MORPHOLOGY; NONHUMAN; PERFUSION; PRIORITY JOURNAL; SUSPENSION CELL CULTURE; VIRION; VIRUS; VIRUS CULTURE; VIRUS PARTICLE;

BATCH VERSUS PERFUSION CULTURE; CELL-DENSITY EFFECT; CELL-SPECIFIC VIRUS YIELD; INFLUENZA; MEMBRANE CUT-OFF; SUSPENSION CELLS;

ANIMALS; BATCH CELL CULTURE TECHNIQUES; BIOREACTORS; BIRDS; CELL COUNT; CELL CULTURE TECHNIQUES; CELL LINE; CULTURE MEDIA; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; PERFUSION; VIRUS CULTIVATION;

EID: 84899925061     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.02.016     Document Type: Article

References (32)

1. Woodside S.M., Bowen B.D., Piret J.M. Mammalian cell retention devices for stirred perfusion bioreactors. Cytotechnology 1998, 28(1-3):163-175.
2. Hu W.S., Peshwa M.V. Animal-cell bioreactors - recent advances and challenges to scale-up. Canadian Journal of Chemical Engineering 1991, 69(2):409-420.
3. Shirgaonkar I.Z., Lanthier S., Kamen A. Acoustic cell filter: a proven cell retention technology for perfusion of animal cell cultures. Biotechnology Advances 2004, 22(6):433-444.
4. Voisard D., Meuwly F., Ruffieux P.A., Baer G., Kadouri A. Potential of cell retention techniques for large-scale high-density perfusion culture of suspended mammalian cells. Biotechnology and Bioengineering 2003, 82(7):751-765.
5. Kyung Y.S., Peshwa M.V., Gryte D.M., Hu W.S. High density culture of mammalian cells with dynamic perfusion based on on-line oxygen uptake rate measurements. Cytotechnology 1994, 14(3):183-190.
6. Warnock J.N., Al-Rubeai M. Bioreactor systems for the production of biopharmaceuticals from animal cells. Biotechnology and Applied Biochemistry 2006, 45(Pt 1):1-12.
7. Clincke M.F., Molleryd C., Zhang Y., Lindskog E., Walsh K., Chotteau V. Study of a recombinant CHO cell line producing a monoclonal antibody by ATF or TFF external filter perfusion in a WAVE bioreactor. BMC Proceedings 2011, 5(Suppl. 8):P105.
8. Wang L., Hu H., Yang J., Wang F., Kaisermayer C., Zhou P. High yield of human monoclonal antibody produced by stably transfected Drosophila Schneider 2 cells in perfusion culture using wave bioreactor. Molecular Biotechnology 2012, 52(2):170-179.
9. Henry O., Dormond E., Perrier M., Kamen A. Insights into adenoviral vector production kinetics in acoustic filter-based perfusion cultures. Biotechnology and Bioengineering 2004, 86(7):765-774.
10. Maranga L., Aunins J.G., Zhou W. Characterization of changes in PER.C6 cellular metabolism during growth and propagation of a replication-deficient adenovirus vector. Biotechnology and Bioengineering 2005, 90(5):645-655.
11. Nadeau I., Kamen A. Production of adenovirus vector for gene therapy. Biotechnology Advances 2003, 20(7-8):475-489.
12. ® cells for the manufacture of biopharmaceutical proteins. Modern Biopharmaceuticals: Design, Development and Optimization 2008, 779-806. Wiley-VCH Verlag GmbH, Weinheim, Germany. J. Knäblein (Ed.).
13. Luitjens A, van Herk H, inventors. Method for the production of AD26 adenoviral vectors patent WO2011098592 (A1); 2011.
14. Kuczewski M., Schirmer E., Lain B., Zarbis-Papastoitsis G. A single-use purification process for the production of a monoclonal antibody produced in a PER.C6 human cell line. Biotechnology Journal 2011, 6(1):56-65.
15. Crowley J, Wuebben M, Coco Martin JM, inventors. Process for cell culturing by continuous perfusion and alternating tangential flow patent WO2005095578 (A1); 2005.
16. Yuk I.H.Y., Olsen M.M., Geyer S., Forestell S.P. Perfusion cultures of human tumor cells: a scalable production platform for oncolytic adenoviral vectors. Biotechnology and Bioengineering 2004, 86(6):637-642.
17. Henry O., Perrier M., Kamen A. Metabolic flux analysis of HEK-293 cells in perfusion cultures for the production of adenoviral vectors. Metabolic Engineering 2005, 7(5-6):467-476.
18. Petiot E., Jacob D., Lanthier S., Lohr V., Ansorge S., Kamen A.A. Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnology 2011, 11:84.
19. Bock A., Schulze-Horsel J., Schwarzer J., Rapp E., Genzel Y., Reichl U. High-density microcarrier cell cultures for influenza virus production. Biotechnology Progress 2011, 27(1):241-250.
20. Lohr V., Rath A., Genzel Y., Jordan I., Sandig V., Reichl U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 2009, 27(36):4975-4982.
21. Jordan I., Vos A., Beilfuss S., Neubert A., Breul S., Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine 2009, 27(5):748-756.
22. Genzel Y., Behrendt I., Rödig J., Rapp E., Kueppers C., Kochanek S., et al. CAP, a new human suspension cell line for influenza virus production. Applied Microbiology Biotechnology 2013, 97(1):111-122.
23. Jordan I., Northoff S., Thiele M., Hartmann S., Horn D., Howing K., et al. A chemically defined production process for highly attenuated poxviruses. Biologicals: Journal of the International Association of Biological Standardization 2011, 39(1):50-58.
24. Kalbfuss B., Knöchlein A., Kröber T., Reichl U. Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals: Journal of the International Association of Biological Standardization 2008, 36(3):145-161.
25. Genzel Y., Reichl U. Vaccine production - state of the art and future needs in upstream processing. Methods in Biotechnology: Animal Cell Biotechnology - Methods and Protocols 2007, 457-473. Humana Press Inc., Totowa, NJ. R. Pörtner (Ed.).
26. Genzel Y., Behrendt I., König S., Sann H., Reichl U. Metabolism of MDCK cells during cell growth and influenza virus production in large-scale microcarrier culture. Vaccine 2004, 22(17-18):2202-2208.
27. Lohr V., Genzel Y., Jordan I., Katinger D., Mahr S., Sandig V., et al. Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells. BMC Biotechnology 2012, 12:79.
28. Xie L.Z., Metallo C., Warren J., Pilbrough W., Peltier J., Zhong T., et al. Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER.C6 (TM) cell culture under sparging conditions. Biotechnology and Bioengineering 2003, 83(1):45-52.
29. 2) oxygen uptake rates in animal cell cultures. Journal of Biotechnology 1998, 63(2):85-95.
30. Wickramasinghe S.R., Kalbfuss B., Zimmermann A., Thom V., Reichl U. Tangential flow microfiltration and ultrafiltration for human influenza A virus concentration and purification. Biotechnology and Bioengineering 2005, 92(2):199-208.
31. Subramanian S., Altaras G.M., Chen J., Hughes B.S., Zhou W.C., Altaras N.E. Pilot-scale adenovirus seed production through concurrent virus release and concentration by hollow fiber filtration. Biotechnology Progress 2005, 21(3):851-859.
32. Le Ru A., Jacob D., Transfiguracion J., Ansorge S., Henry O., Kamen A.A. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine 2010, 28(21):3661-3671.